Report from Annual General Meeting of Vitrolife AB (publ)
Vitrolife AB held its Annual General Meeting on April 29, 2025, announcing key decisions including a dividend of SEK 1.10 per share for 2024. The board saw the re-election of members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson, and Karen Lykke Sørensen, with Jón Sigurdsson elected as Chairman.
Board remuneration was increased to SEK 3.67 million, with the Chairman receiving SEK 1.35 million. The company authorized potential issuance of up to 13,544,719 shares (10% of share capital) and approved share buyback authorization. Deloitte AB was re-elected as auditor.
The meeting also approved new executive management compensation guidelines and resolved to enter a share swap agreement for LTIP 2025 implementation.
Vitrolife AB ha tenuto la sua Assemblea Generale Annuale il 29 aprile 2025, annunciando decisioni importanti tra cui un dividendo di 1,10 SEK per azione relativo al 2024. Il consiglio ha visto la rielezione dei membri Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson e Karen Lykke Sørensen, con Jón Sigurdsson eletto Presidente.
La remunerazione del consiglio è stata aumentata a 3,67 milioni di SEK, con il Presidente che riceverà 1,35 milioni di SEK. La società ha autorizzato l’emissione potenziale fino a 13.544.719 azioni (pari al 10% del capitale sociale) e ha approvato l’autorizzazione al riacquisto di azioni. Deloitte AB è stata rieletta come revisore.
L’assemblea ha inoltre approvato nuove linee guida per la remunerazione del management esecutivo e ha deciso di stipulare un accordo di scambio azionario per l’implementazione del LTIP 2025.
Vitrolife AB celebró su Junta General Anual el 29 de abril de 2025, anunciando decisiones clave, incluyendo un dividendo de 1,10 SEK por acción para 2024. La junta reelegió a los miembros Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson y Karen Lykke Sørensen, siendo Jón Sigurdsson elegido Presidente.
La remuneración del consejo aumentó a 3,67 millones de SEK, con el Presidente recibiendo 1,35 millones de SEK. La empresa autorizó la posible emisión de hasta 13.544.719 acciones (el 10% del capital social) y aprobó la autorización para la recompra de acciones. Deloitte AB fue reelegida como auditor.
La junta también aprobó nuevas directrices de compensación para la alta dirección y decidió celebrar un acuerdo de intercambio de acciones para la implementación del LTIP 2025.
Vitrolife AB는 2025년 4월 29일 연례 주주총회를 개최하여 2024년 주당 1.10 SEK 배당금을 포함한 주요 결정을 발표했습니다. 이사회는 Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson, Karen Lykke Sørensen의 재선임을 승인했으며 Jón Sigurdsson이 이사회 의장으로 선출되었습니다.
이사회 보수는 367만 SEK로 인상되었으며, 의장은 135만 SEK를 받게 됩니다. 회사는 최대 13,544,719주(자본금의 10%) 발행을 승인하고 자사주 매입 권한도 승인했습니다. Deloitte AB가 감사로 재선임되었습니다.
총회는 또한 새로운 경영진 보상 지침을 승인하고 LTIP 2025 실행을 위한 주식 교환 계약 체결을 결의했습니다.
Vitrolife AB a tenu son Assemblée Générale Annuelle le 29 avril 2025, annonçant des décisions clés, y compris un dividende de 1,10 SEK par action pour 2024. Le conseil d'administration a vu la réélection des membres Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson et Karen Lykke Sørensen, Jón Sigurdsson étant élu Président.
La rémunération du conseil a été portée à 3,67 millions de SEK, le Président recevant 1,35 million de SEK. La société a autorisé l’émission potentielle de jusqu’à 13 544 719 actions (soit 10 % du capital social) et a approuvé une autorisation de rachat d’actions. Deloitte AB a été réélue en tant que commissaire aux comptes.
L’assemblée a également approuvé de nouvelles directives de rémunération pour la direction exécutive et a décidé de conclure un accord d’échange d’actions pour la mise en œuvre du LTIP 2025.
Vitrolife AB hielt am 29. April 2025 seine Hauptversammlung ab und gab wichtige Entscheidungen bekannt, darunter eine Dividende von 1,10 SEK je Aktie für 2024. Der Vorstand wurde mit Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson und Karen Lykke Sørensen wiedergewählt, wobei Jón Sigurdsson zum Vorsitzenden gewählt wurde.
Die Vergütung des Vorstands wurde auf 3,67 Millionen SEK erhöht, der Vorsitzende erhält 1,35 Millionen SEK. Das Unternehmen genehmigte die potenzielle Ausgabe von bis zu 13.544.719 Aktien (10 % des Aktienkapitals) und bewilligte eine Rückkaufgenehmigung. Deloitte AB wurde als Abschlussprüfer wiedergewählt.
Die Versammlung genehmigte außerdem neue Vergütungsrichtlinien für das Executive Management und beschloss den Abschluss eines Aktientauschvertrags zur Umsetzung des LTIP 2025.
- Dividend payment of SEK 1.10 per share approved for 2024
- Board authorization to issue up to 13.5M new shares (10% of capital) for potential growth opportunities
- Increased board remuneration indicating company growth (total SEK 3.67M vs previous 3.3M)
- Potential shareholder dilution risk from 10% share issuance authorization
- Authorization for share buybacks up to 10% could reduce market liquidity
- Higher board compensation increases administrative expenses
- Resolution in accordance with the Board's proposed dividend of
SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. - Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Jón Sigurdsson was elected Chairman of the Board.
- Remuneration to the Board members is proposed to be in total
SEK 3 670 000 (3 300 000) of whichSEK 1 350 000 (1 200 000) to the Chairman of the Board,SEK 450 000 (400 000) to each of the other members of the Board,SEK 160 000 (150 000) to the Chairman of the Audit Committee andSEK 80 000 (75 000) to each of the other members of the Audit Committee. - The Election Committee proposes re-election of the auditor Deloitte AB and with unchanged remuneration principles.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
- Resolution to entering a share swap agreement in order to secure delivery of shares to participants in LTIP 2025 and the potential financial impacts of LTIP 2025.
VITROLIFE AB (publ)
The Board
The information was submitted for publication, through the agency of the contact persons set out above, at 29-04-2025 16:56 CET.
Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Report from Annual General Meeting of Vitrolife AB (publ) |
View original content:https://www.prnewswire.com/news-releases/report-from-annual-general-meeting-of-vitrolife-ab-publ-302441477.html
SOURCE Vitrolife AB (publ)
FAQ
What dividend did Vitrolife (VTRLY) announce for 2024?
How many shares is Vitrolife (VTRLY) authorized to issue in 2025?
What is the new Board compensation structure for Vitrolife (VTRLY) in 2025?
Who was elected as Vitrolife's (VTRLY) Board Chairman in 2025?
What share buyback limit was approved for Vitrolife (VTRLY)?
